Jazz Pharmaceuticals Announces CEO Succession Plan
| JAZZ Stock | USD 120.56 3.20 2.59% |
Slightly above 67% of Jazz Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading Jazz Pharmaceuticals PLC stock suggests that many investors are alarmed at this time. Jazz Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Jazz Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Jazz |
Summary Jazz Pharmaceuticals PLC announced on December 16, 2024, that its Co-Founder, Chairperson, and CEO, Bruce Cozadd, plans to retire from his CEO ro
Read at gurufocus.com
 |
Jazz Pharmaceuticals Fundamental Analysis
We analyze Jazz Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jazz Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jazz Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Employees
Number Of Employees Comparative Analysis
Jazz Pharmaceuticals is currently under evaluation in number of employees category among its peers. Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Jazz Pharmaceuticals PLC Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Jazz Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Jazz Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Jazz Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Jazz Pharmaceuticals Related Equities
| INBX | Inhibrx | 5.90 | ||||
| LRMR | Larimar Therapeutics | 4.24 | ||||
| TECH | Bio Techne | 3.23 | ||||
| LEGN | Legend Biotech | 3.02 | ||||
| VRDN | Viridian Therapeutics | 2.18 | ||||
| DNLI | Denali Therapeutics | 2.02 | ||||
| PCVX | Vaxcyte | 1.87 | ||||
| ASND | Ascendis Pharma | 1.74 | ||||
| LQDA | Liquidia Technologies | 1.57 | ||||
| PTGX | Protagonist Therapeutics | 1.51 | ||||
| BPMC | Blueprint Medicines | 1.32 | ||||
| APLS | Apellis Pharmaceuticals | 0.90 | ||||
| RARE | Ultragenyx | 0.85 | ||||
| BMRN | Biomarin Pharmaceutical | 0.51 | ||||
| ALNY | Alnylam Pharmaceuticals | 0.28 | ||||
| ARGX | Argenx NV | 0.18 | ||||
| INCY | Incyte | 0.14 | ||||
| EXEL | Exelixis | 0.09 | ||||
| HALO | Halozyme Therapeutics | 0.56 | ||||
| UTHR | United Therapeutics | 1.08 |
Additional Tools for Jazz Stock Analysis
When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.